REVIEW ON DRUG REPURPOSING FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and neuronal death. Despite extensive research, effective disease-modifying treatments are limited. Drug repurposing, which identifies new therapeutic uses for existing drugs, offers a promising and cost-effective strategy for accelerating the discovery of AD treatments. This approach leverages the known safety profiles and pharmacokinetics of approved drugs to target Alzheimer’s-related mechanisms, such as amyloid-beta aggregation, tau protein hyperphosphorylation, oxidative stress, and neuroinflammation. Several repurposed candidates, including antidiabetic agents (metformin), antihypertensives, antidepressants, and anti-inflammatory drugs, have demonstrated potential neuroprotective effects in both preclinical and clinical studies. Overall, drug repurposing represents a practical and efficient pathway to uncover novel therapies for Alzheimer’s disease, potentially shortening development timelines and improving patient outcomes.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-02-16
DOI
https://doi.org/10.5281/zenodo.18657137
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

REVIEW ON DRUG REPURPOSING FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Vinjavarapu L. Anusha*, Buddapu Mounika Rani1, L. Samathasri1, Maradani Sirisha1, K. Jahnavi1, V. Pardhasaradhi1, O. Roddick Meitei1, P. Anil Kumar1, P. Poojitha1, K. Bhuvana Naga Sai Sri1, K. Jaswanthi1, K. Pravallika1
Zenodo (CERN European Organization for Nuclear Research)
Alzheimer's disease research and treatments
article

REVIEW ON DRUG REPURPOSING FOR THE TREATMENT OF ALZHEIMER'S DISEASE

Vinjavarapu L. Anusha*, Buddapu Mounika Rani1, L. Samathasri1, Maradani Sirisha1, K. Jahnavi1, V. Pardhasaradhi1, O. Roddick Meitei1, P. Anil Kumar1, P. Poojitha1, K. Bhuvana Naga Sai Sri1, K. Jaswanthi1, K. Pravallika1
article en

Abstract

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and neuronal death. Despite extensive research, effective disease-modifying treatments are limited. Drug repurposing, which identifies new therapeutic uses for existing drugs, offers a promising and cost-effective strategy for accelerating the discovery of AD treatments. This approach leverages the known safety profiles and pharmacokinetics of approved drugs to target Alzheimer’s-related mechanisms, such as amyloid-beta aggregation, tau protein hyperphosphorylation, oxidative stress, and neuroinflammation. Several repurposed candidates, including antidiabetic agents (metformin), antihypertensives, antidepressants, and anti-inflammatory drugs, have demonstrated potential neuroprotective effects in both preclinical and clinical studies. Overall, drug repurposing represents a practical and efficient pathway to uncover novel therapies for Alzheimer’s disease, potentially shortening development timelines and improving patient outcomes.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 52%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

REVIEW ON DRUG REPURPOSING FOR THE TREATMENT OF ALZHEIMER'S DISEASE — Vinjavarapu L. Anusha*, Buddapu Mounika Rani1, L. Samathasri1, Maradani Sirisha1, K. Jahnavi1, V. Pardhasaradhi1, O. Roddick Meitei1, P. Anil Kumar1, P. Poojitha1, K. Bhuvana Naga Sai Sri1, K. Jaswanthi1, K. Pravallika1 · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS